BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 30582717)

  • 21. Calcipotriol and betamethasone dipropionate exhibit different immunomodulatory effects on imiquimod-induced murine psoriasiform dermatitis.
    Takeoka S; Shimizu T; Kamata M; Hau CS; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
    J Dermatol; 2020 Feb; 47(2):155-162. PubMed ID: 31762070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calcipotriol/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data.
    Megna M; Cinelli E; Camela E; Fabbrocini G
    Expert Rev Clin Immunol; 2020 Jun; 16(6):599-620. PubMed ID: 32476507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam.
    Jalili A; Lebwohl M; Stein Gold L; Andersen SB; Jensen KL; Pink AE; Segaert S; Berg P; Calzavara-Pinton PG; de la Cueva Dobao P; Thaçi D
    J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):709-717. PubMed ID: 30520168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris.
    Kaufmann R; Bibby AJ; Bissonnette R; Cambazard F; Chu AC; Decroix J; Douglas WS; Lowson D; Mascaro JM; Murphy GM; Stymne B
    Dermatology; 2002; 205(4):389-93. PubMed ID: 12444337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spotlight on calcipotriene/betamethasone dipropionate in psoriasis vulgaris of the trunk, limbs, and scalp.
    McCormack PL
    Am J Clin Dermatol; 2011 Dec; 12(6):421-4. PubMed ID: 21967117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial.
    Guenther L; Van de Kerkhof PC; Snellman E; Kragballe K; Chu AC; Tegner E; Garcia-Diez A; Springborg J
    Br J Dermatol; 2002 Aug; 147(2):316-23. PubMed ID: 12174105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study.
    Lambert J; Hol CW; Vink J
    J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2349-55. PubMed ID: 26337069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis.
    Wu JJ; Hansen JB; Patel DS; Nyholm N; Veverka KA; Swensen AR
    J Med Econ; 2020 Jun; 23(6):641-649. PubMed ID: 31985301
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy, safety, and cost-effectiveness of all-trans retinoic acid/Clobetasol Propionate Compound Ointment in the treatment of mild to moderate psoriasis vulgaris: A randomized, single-blind, multicenter clinical trial.
    Xia L; Li R; Wang Y; Lin Z; Zheng J; Li X; Lu Q; Zhang J; Jin H; Fu L; Zhang X; Liu Y; Yang S; Xiao F; Gao XH
    Dermatol Ther; 2018 Sep; 31(5):e12632. PubMed ID: 30253049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: 4- and 12-week interim results from the PRO-long study.
    Lambert J; Hol CW; Vink J
    J Eur Acad Dermatol Venereol; 2014 Dec; 28(12):1723-31. PubMed ID: 24533503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of psoriasis vulgaris with the two-compound product calcipotriol/betamethasone dipropionate followed by different formulations of calcipotriol.
    Cassano N; Miracapillo A; Coviello C; Loconsole F; Bellino M; Vena GA
    Clin Drug Investig; 2006; 26(4):227-33. PubMed ID: 17163256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study.
    Paul C; Leonardi C; Menter A; Reich K; Gold LS; Warren RB; Møller A; Lebwohl M
    Am J Clin Dermatol; 2017 Jun; 18(3):405-411. PubMed ID: 28236223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early efficacy and safety data with fixed-dose combination calcipotriol/betamethasone dipropionate foam attributed to mechanism of absorption and steroid potency.
    Tada Y; Iversen L; Koo J
    J Eur Acad Dermatol Venereol; 2021 Feb; 35 Suppl 1(Suppl 1):5-9. PubMed ID: 33619779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy.
    Kragballe K; Barnes L; Hamberg KJ; Hutchinson P; Murphy F; Møller S; Ruzicka T; Van De Kerkhof PC
    Br J Dermatol; 1998 Oct; 139(4):649-54. PubMed ID: 9892908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Calcipotriol/Betamethasone Dipropionate Foam: A Review in Plaque Psoriasis.
    Kim ES; Frampton JE
    Drugs; 2016 Oct; 76(15):1485-1492. PubMed ID: 27663245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Topical calcipotriol plus betamethasone dipropionate for the treatment of plaque psoriasis: a drug evaluation.
    Purvis CG; Balogh EA; Heron CE; Feldman SR
    Expert Opin Pharmacother; 2021 Jun; 22(9):1107-1118. PubMed ID: 33745399
    [No Abstract]   [Full Text] [Related]  

  • 37. Calcipotriol/betamethasone dipropionate aerosol foam in the treatment of psoriasis: new perspectives for the use of an innovative topical treatment from real-life experience.
    Fabbrocini G; Dauden E; Jalili A; Bewley A
    G Ital Dermatol Venereol; 2020 Apr; 155(2):212-219. PubMed ID: 32394674
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial).
    Lebwohl M; Kircik L; Lacour JP; Liljedahl M; Lynde C; Mørch MH; Papp KA; Perrot JL; Gold LS; Takhar A; Thaçi D; Warren RB; Wollenberg A
    J Am Acad Dermatol; 2021 May; 84(5):1269-1277. PubMed ID: 32950546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the antipsoriatic effect and tolerability of calcipotriol-containing products in the treatment of psoriasis vulgaris using a modified psoriasis plaque test.
    Queille-Roussel C; Hoffmann V; Ganslandt C; Hansen KK
    Clin Drug Investig; 2012 Sep; 32(9):613-9. PubMed ID: 22845045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasis.
    Papp KA; Thoning H; Gerdes S; Megna M; Brandi H; Jablonski Bernasconi MY; Yélamos O
    J Dermatolog Treat; 2022 Nov; 33(7):3005-3013. PubMed ID: 35875991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.